ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-32G19062
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Nucleoside Antiviral Active Pharmaceutical Ingredient API Market Research Report 2025
BUY CHAPTERS

Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Research Report 2025

Code: QYRE-Auto-32G19062
Report
March 2025
Pages:116
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Fuxiang Pharmaceuticals
Hongyuan Pharmaceuticals
Xinxiang Pharmaceuticals
Hubei Yitai Pharmaceuticals
Shanghai Pharmaceuticals Kangli
Zhejiang Chetou Pharmaceuticals
Atom Pharma
Clearsynth
Mylan NV
Hetero Drugs
Cipla Ltd
Nortec Quimica
Globe Quimica Ltda
Octavius Pharma
Apotex Pharmachem
Zhejiang Zhebei Pharmaceuticals
Chongqing Qingyang Pharmaceuticals
Zhejiang Chengyi Pharmaceuticals
Tianjin Junan Biopharmaceuticals
Mangalam
Adrovent Pharma
Vinuthana

Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size

The global market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) was valued at US$ 341 million in the year 2024 and is projected to reach a revised size of US$ 520 million by 2031, growing at a CAGR of 6.2% during the forecast period.

Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market

Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market

A nucleoside antiviral active pharmaceutical ingredient (API) is a chemically synthesized or biologically derived compound used as the key component in antiviral medications. These APIs mimic natural nucleosides and interfere with viral DNA or RNA replication, effectively inhibiting virus proliferation. Common examples include acyclovir, zidovudine, lamivudine, and entecavir.
North American market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) include Fuxiang Pharmaceuticals, Zhejiang Zhebei Pharmaceuticals, Hongyuan Pharmaceuticals, Xinxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals, Chongqing Qingyang Pharmaceuticals, Zhejiang Chengyi Pharmaceuticals, Tianjin Junan Biopharmaceuticals, Shanghai Pharmaceuticals Kangli, Zhejiang Chetou Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Nucleoside Antiviral Active Pharmaceutical Ingredient (API), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleoside Antiviral Active Pharmaceutical Ingredient (API).
The Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Report

Report Metric Details
Report Name Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market
Accounted market size in year US$ 341 million
Forecasted market size in 2031 US$ 520 million
CAGR 6.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Acyclovir API
  • Zidovudine API
  • Entecavir API
  • Sofosbuvir API
  • Other
Segment by Application
  • Pharmaceuticals
  • Scientific Research
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Fuxiang Pharmaceuticals, Zhejiang Zhebei Pharmaceuticals, Hongyuan Pharmaceuticals, Xinxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals, Chongqing Qingyang Pharmaceuticals, Zhejiang Chengyi Pharmaceuticals, Tianjin Junan Biopharmaceuticals, Shanghai Pharmaceuticals Kangli, Zhejiang Chetou Pharmaceuticals, Mangalam, Adrovent Pharma, Vinuthana, Atom pharma, Clearsynth, Mylan, Hetero Drugs, Cipla, Nortec Quimica, Globe Quimica Ltda, Octavius Pharma, Apotex Pharmachem
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market growing?

Ans: The Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market size in 2031?

Ans: The Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market size in 2031 will be US$ 520 million.

Who are the main players in the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market report?

Ans: The main players in the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market are Fuxiang Pharmaceuticals, Zhejiang Zhebei Pharmaceuticals, Hongyuan Pharmaceuticals, Xinxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals, Chongqing Qingyang Pharmaceuticals, Zhejiang Chengyi Pharmaceuticals, Tianjin Junan Biopharmaceuticals, Shanghai Pharmaceuticals Kangli, Zhejiang Chetou Pharmaceuticals, Mangalam, Adrovent Pharma, Vinuthana, Atom pharma, Clearsynth, Mylan, Hetero Drugs, Cipla, Nortec Quimica, Globe Quimica Ltda, Octavius Pharma, Apotex Pharmachem

What are the Application segmentation covered in the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market report?

Ans: The Applications covered in the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market report are Pharmaceuticals, Scientific Research

What are the Type segmentation covered in the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market report?

Ans: The Types covered in the Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market report are Acyclovir API, Zidovudine API, Entecavir API, Sofosbuvir API, Other

1 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Overview
1.1 Product Definition
1.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Type
1.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Value Comparison by Type (2024 VS 2031)
1.2.2 Acyclovir API
1.2.3 Zidovudine API
1.2.4 Entecavir API
1.2.5 Sofosbuvir API
1.2.6 Other
1.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Application
1.3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Value by Application (2024 VS 2031)
1.3.2 Pharmaceuticals
1.3.3 Scientific Research
1.4 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size Estimates and Forecasts
1.4.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue 2020-2031
1.4.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales 2020-2031
1.4.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Competition by Manufacturers
2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Manufacturers (2020-2025)
2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Product Type & Application
2.7 Global Key Manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Date of Enter into This Industry
2.8 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Competitive Situation and Trends
2.8.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Players Market Share by Revenue
2.8.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Scenario by Region
3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region: 2020-2031
3.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region: 2020-2025
3.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region: 2026-2031
3.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region: 2020-2031
3.3.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region: 2020-2025
3.3.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region: 2026-2031
3.4 North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Facts & Figures by Country
3.4.1 North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2031)
3.4.3 North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Facts & Figures by Country
3.5.1 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2031)
3.5.3 Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Facts & Figures by Region
3.6.1 Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2031)
3.6.3 Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Facts & Figures by Country
3.7.1 Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2031)
3.7.3 Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Facts & Figures by Country
3.8.1 Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2031)
3.8.3 Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2031)
4.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
4.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Type (2026-2031)
4.1.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2031)
4.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Type (2020-2031)
4.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Type (2020-2025)
4.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Type (2026-2031)
4.2.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2020-2031)
4.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price by Type (2020-2031)
5 Segment by Application
5.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2031)
5.1.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
5.1.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Application (2026-2031)
5.1.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2031)
5.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Application (2020-2031)
5.2.1 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Application (2020-2025)
5.2.2 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Application (2026-2031)
5.2.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application (2020-2031)
5.3 Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Fuxiang Pharmaceuticals
6.1.1 Fuxiang Pharmaceuticals Company Information
6.1.2 Fuxiang Pharmaceuticals Description and Business Overview
6.1.3 Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.1.5 Fuxiang Pharmaceuticals Recent Developments/Updates
6.2 Zhejiang Zhebei Pharmaceuticals
6.2.1 Zhejiang Zhebei Pharmaceuticals Company Information
6.2.2 Zhejiang Zhebei Pharmaceuticals Description and Business Overview
6.2.3 Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.2.5 Zhejiang Zhebei Pharmaceuticals Recent Developments/Updates
6.3 Hongyuan Pharmaceuticals
6.3.1 Hongyuan Pharmaceuticals Company Information
6.3.2 Hongyuan Pharmaceuticals Description and Business Overview
6.3.3 Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.3.5 Hongyuan Pharmaceuticals Recent Developments/Updates
6.4 Xinxiang Pharmaceuticals
6.4.1 Xinxiang Pharmaceuticals Company Information
6.4.2 Xinxiang Pharmaceuticals Description and Business Overview
6.4.3 Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.4.5 Xinxiang Pharmaceuticals Recent Developments/Updates
6.5 Hubei Yitai Pharmaceuticals
6.5.1 Hubei Yitai Pharmaceuticals Company Information
6.5.2 Hubei Yitai Pharmaceuticals Description and Business Overview
6.5.3 Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.5.5 Hubei Yitai Pharmaceuticals Recent Developments/Updates
6.6 Chongqing Qingyang Pharmaceuticals
6.6.1 Chongqing Qingyang Pharmaceuticals Company Information
6.6.2 Chongqing Qingyang Pharmaceuticals Description and Business Overview
6.6.3 Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.6.5 Chongqing Qingyang Pharmaceuticals Recent Developments/Updates
6.7 Zhejiang Chengyi Pharmaceuticals
6.7.1 Zhejiang Chengyi Pharmaceuticals Company Information
6.7.2 Zhejiang Chengyi Pharmaceuticals Description and Business Overview
6.7.3 Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.7.5 Zhejiang Chengyi Pharmaceuticals Recent Developments/Updates
6.8 Tianjin Junan Biopharmaceuticals
6.8.1 Tianjin Junan Biopharmaceuticals Company Information
6.8.2 Tianjin Junan Biopharmaceuticals Description and Business Overview
6.8.3 Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.8.5 Tianjin Junan Biopharmaceuticals Recent Developments/Updates
6.9 Shanghai Pharmaceuticals Kangli
6.9.1 Shanghai Pharmaceuticals Kangli Company Information
6.9.2 Shanghai Pharmaceuticals Kangli Description and Business Overview
6.9.3 Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.9.5 Shanghai Pharmaceuticals Kangli Recent Developments/Updates
6.10 Zhejiang Chetou Pharmaceuticals
6.10.1 Zhejiang Chetou Pharmaceuticals Company Information
6.10.2 Zhejiang Chetou Pharmaceuticals Description and Business Overview
6.10.3 Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.10.5 Zhejiang Chetou Pharmaceuticals Recent Developments/Updates
6.11 Mangalam
6.11.1 Mangalam Company Information
6.11.2 Mangalam Description and Business Overview
6.11.3 Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.11.5 Mangalam Recent Developments/Updates
6.12 Adrovent Pharma
6.12.1 Adrovent Pharma Company Information
6.12.2 Adrovent Pharma Description and Business Overview
6.12.3 Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.12.5 Adrovent Pharma Recent Developments/Updates
6.13 Vinuthana
6.13.1 Vinuthana Company Information
6.13.2 Vinuthana Description and Business Overview
6.13.3 Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.13.5 Vinuthana Recent Developments/Updates
6.14 Atom pharma
6.14.1 Atom pharma Company Information
6.14.2 Atom pharma Description and Business Overview
6.14.3 Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.14.5 Atom pharma Recent Developments/Updates
6.15 Clearsynth
6.15.1 Clearsynth Company Information
6.15.2 Clearsynth Description and Business Overview
6.15.3 Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.15.5 Clearsynth Recent Developments/Updates
6.16 Mylan
6.16.1 Mylan Company Information
6.16.2 Mylan Description and Business Overview
6.16.3 Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.16.5 Mylan Recent Developments/Updates
6.17 Hetero Drugs
6.17.1 Hetero Drugs Company Information
6.17.2 Hetero Drugs Description and Business Overview
6.17.3 Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.17.5 Hetero Drugs Recent Developments/Updates
6.18 Cipla
6.18.1 Cipla Company Information
6.18.2 Cipla Description and Business Overview
6.18.3 Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.18.5 Cipla Recent Developments/Updates
6.19 Nortec Quimica
6.19.1 Nortec Quimica Company Information
6.19.2 Nortec Quimica Description and Business Overview
6.19.3 Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.19.5 Nortec Quimica Recent Developments/Updates
6.20 Globe Quimica Ltda
6.20.1 Globe Quimica Ltda Company Information
6.20.2 Globe Quimica Ltda Description and Business Overview
6.20.3 Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.20.5 Globe Quimica Ltda Recent Developments/Updates
6.21 Octavius Pharma
6.21.1 Octavius Pharma Company Information
6.21.2 Octavius Pharma Description and Business Overview
6.21.3 Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.21.5 Octavius Pharma Recent Developments/Updates
6.22 Apotex Pharmachem
6.22.1 Apotex Pharmachem Company Information
6.22.2 Apotex Pharmachem Description and Business Overview
6.22.3 Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product Portfolio
6.22.5 Apotex Pharmachem Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Industry Chain Analysis
7.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Production Mode & Process Analysis
7.4 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales and Marketing
7.4.1 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Channels
7.4.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Distributors
7.5 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Customer Analysis
8 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Dynamics
8.1 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Industry Trends
8.2 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Drivers
8.3 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Challenges
8.4 Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Fuxiang Pharmaceuticals
Hongyuan Pharmaceuticals
Xinxiang Pharmaceuticals
Hubei Yitai Pharmaceuticals
Shanghai Pharmaceuticals Kangli
Zhejiang Chetou Pharmaceuticals
Atom Pharma
Clearsynth
Mylan NV
Hetero Drugs
Cipla Ltd
Nortec Quimica
Globe Quimica Ltda
Octavius Pharma
Apotex Pharmachem
Zhejiang Zhebei Pharmaceuticals
Chongqing Qingyang Pharmaceuticals
Zhejiang Chengyi Pharmaceuticals
Tianjin Junan Biopharmaceuticals
Mangalam
Adrovent Pharma
Vinuthana
List of Tables
 Table 1. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons) of Key Manufacturers (2020-2025)
 Table 5. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Average Price (US$/Ton) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Product Type & Application
 Table 12. Global Key Manufacturers of Nucleoside Antiviral Active Pharmaceutical Ingredient (API), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleoside Antiviral Active Pharmaceutical Ingredient (API) as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025) & (Tons)
 Table 18. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region (2020-2025)
 Table 19. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2026-2031) & (Tons)
 Table 20. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region (2026-2031)
 Table 21. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Region (2020-2025)
 Table 23. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Region (2026-2031)
 Table 25. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
 Table 27. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2026-2031) & (Tons)
 Table 28. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
 Table 32. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2026-2031) & (Tons)
 Table 33. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025) & (Tons)
 Table 37. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Region (2026-2031) & (Tons)
 Table 38. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
 Table 42. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2026-2031) & (Tons)
 Table 43. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025) & (Tons)
 Table 47. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales by Country (2026-2031) & (Tons)
 Table 48. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons) by Type (2020-2025)
 Table 51. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons) by Type (2026-2031)
 Table 52. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
 Table 53. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2026-2031)
 Table 54. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2020-2025)
 Table 57. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Type (2026-2031)
 Table 58. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price (US$/Ton) by Type (2020-2025)
 Table 59. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price (US$/Ton) by Type (2026-2031)
 Table 60. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons) by Application (2020-2025)
 Table 61. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons) by Application (2026-2031)
 Table 62. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2020-2025)
 Table 63. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Application (2026-2031)
 Table 64. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application (2020-2025)
 Table 67. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Application (2026-2031)
 Table 68. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price (US$/Ton) by Application (2020-2025)
 Table 69. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price (US$/Ton) by Application (2026-2031)
 Table 70. Fuxiang Pharmaceuticals Company Information
 Table 71. Fuxiang Pharmaceuticals Description and Business Overview
 Table 72. Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 73. Fuxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 74. Fuxiang Pharmaceuticals Recent Developments/Updates
 Table 75. Zhejiang Zhebei Pharmaceuticals Company Information
 Table 76. Zhejiang Zhebei Pharmaceuticals Description and Business Overview
 Table 77. Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 78. Zhejiang Zhebei Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 79. Zhejiang Zhebei Pharmaceuticals Recent Developments/Updates
 Table 80. Hongyuan Pharmaceuticals Company Information
 Table 81. Hongyuan Pharmaceuticals Description and Business Overview
 Table 82. Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 83. Hongyuan Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 84. Hongyuan Pharmaceuticals Recent Developments/Updates
 Table 85. Xinxiang Pharmaceuticals Company Information
 Table 86. Xinxiang Pharmaceuticals Description and Business Overview
 Table 87. Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 88. Xinxiang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 89. Xinxiang Pharmaceuticals Recent Developments/Updates
 Table 90. Hubei Yitai Pharmaceuticals Company Information
 Table 91. Hubei Yitai Pharmaceuticals Description and Business Overview
 Table 92. Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 93. Hubei Yitai Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 94. Hubei Yitai Pharmaceuticals Recent Developments/Updates
 Table 95. Chongqing Qingyang Pharmaceuticals Company Information
 Table 96. Chongqing Qingyang Pharmaceuticals Description and Business Overview
 Table 97. Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 98. Chongqing Qingyang Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 99. Chongqing Qingyang Pharmaceuticals Recent Developments/Updates
 Table 100. Zhejiang Chengyi Pharmaceuticals Company Information
 Table 101. Zhejiang Chengyi Pharmaceuticals Description and Business Overview
 Table 102. Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 103. Zhejiang Chengyi Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 104. Zhejiang Chengyi Pharmaceuticals Recent Developments/Updates
 Table 105. Tianjin Junan Biopharmaceuticals Company Information
 Table 106. Tianjin Junan Biopharmaceuticals Description and Business Overview
 Table 107. Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 108. Tianjin Junan Biopharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 109. Tianjin Junan Biopharmaceuticals Recent Developments/Updates
 Table 110. Shanghai Pharmaceuticals Kangli Company Information
 Table 111. Shanghai Pharmaceuticals Kangli Description and Business Overview
 Table 112. Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 113. Shanghai Pharmaceuticals Kangli Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 114. Shanghai Pharmaceuticals Kangli Recent Developments/Updates
 Table 115. Zhejiang Chetou Pharmaceuticals Company Information
 Table 116. Zhejiang Chetou Pharmaceuticals Description and Business Overview
 Table 117. Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 118. Zhejiang Chetou Pharmaceuticals Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 119. Zhejiang Chetou Pharmaceuticals Recent Developments/Updates
 Table 120. Mangalam Company Information
 Table 121. Mangalam Description and Business Overview
 Table 122. Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 123. Mangalam Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 124. Mangalam Recent Developments/Updates
 Table 125. Adrovent Pharma Company Information
 Table 126. Adrovent Pharma Description and Business Overview
 Table 127. Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 128. Adrovent Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 129. Adrovent Pharma Recent Developments/Updates
 Table 130. Vinuthana Company Information
 Table 131. Vinuthana Description and Business Overview
 Table 132. Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 133. Vinuthana Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 134. Vinuthana Recent Developments/Updates
 Table 135. Atom pharma Company Information
 Table 136. Atom pharma Description and Business Overview
 Table 137. Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 138. Atom pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 139. Atom pharma Recent Developments/Updates
 Table 140. Clearsynth Company Information
 Table 141. Clearsynth Description and Business Overview
 Table 142. Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 143. Clearsynth Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 144. Clearsynth Recent Developments/Updates
 Table 145. Mylan Company Information
 Table 146. Mylan Description and Business Overview
 Table 147. Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 148. Mylan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 149. Mylan Recent Developments/Updates
 Table 150. Hetero Drugs Company Information
 Table 151. Hetero Drugs Description and Business Overview
 Table 152. Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 153. Hetero Drugs Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 154. Hetero Drugs Recent Developments/Updates
 Table 155. Cipla Company Information
 Table 156. Cipla Description and Business Overview
 Table 157. Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 158. Cipla Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 159. Cipla Recent Developments/Updates
 Table 160. Nortec Quimica Company Information
 Table 161. Nortec Quimica Description and Business Overview
 Table 162. Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 163. Nortec Quimica Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 164. Nortec Quimica Recent Developments/Updates
 Table 165. Globe Quimica Ltda Company Information
 Table 166. Globe Quimica Ltda Description and Business Overview
 Table 167. Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 168. Globe Quimica Ltda Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 169. Globe Quimica Ltda Recent Developments/Updates
 Table 170. Octavius Pharma Company Information
 Table 171. Octavius Pharma Description and Business Overview
 Table 172. Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 173. Octavius Pharma Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 174. Octavius Pharma Recent Developments/Updates
 Table 175. Apotex Pharmachem Company Information
 Table 176. Apotex Pharmachem Description and Business Overview
 Table 177. Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
 Table 178. Apotex Pharmachem Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Product
 Table 179. Apotex Pharmachem Recent Developments/Updates
 Table 180. Key Raw Materials Lists
 Table 181. Raw Materials Key Suppliers Lists
 Table 182. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Distributors List
 Table 183. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Customers List
 Table 184. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Trends
 Table 185. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Drivers
 Table 186. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Challenges
 Table 187. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Restraints
 Table 188. Research Programs/Design for This Report
 Table 189. Key Data Information from Secondary Sources
 Table 190. Key Data Information from Primary Sources
 Table 191. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Nucleoside Antiviral Active Pharmaceutical Ingredient (API)
 Figure 2. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Share by Type: 2024 & 2031
 Figure 4. Acyclovir API Product Picture
 Figure 5. Zidovudine API Product Picture
 Figure 6. Entecavir API Product Picture
 Figure 7. Sofosbuvir API Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Share by Application: 2024 & 2031
 Figure 11. Pharmaceuticals
 Figure 12. Scientific Research
 Figure 13. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales (2020-2031) & (Tons)
 Figure 16. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Average Price (US$/Ton) & (2020-2031)
 Figure 17. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Report Years Considered
 Figure 18. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Share by Manufacturers in 2024
 Figure 19. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Players: Market Share by Revenue in Nucleoside Antiviral Active Pharmaceutical Ingredient (API) in 2024
 Figure 21. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2031)
 Figure 24. North America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2031)
 Figure 25. United States Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2031)
 Figure 28. Europe Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Region (2020-2031)
 Figure 36. China Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Colombia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Type (2020-2031)
 Figure 56. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price (US$/Ton) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Nucleoside Antiviral Active Pharmaceutical Ingredient (API) by Application (2020-2031)
 Figure 59. Global Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Price (US$/Ton) by Application (2020-2031)
 Figure 60. Nucleoside Antiviral Active Pharmaceutical Ingredient (API) Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Acyclovir Active Pharmaceutical Ingredient API Market Research Report 2025
Global Lovir Class Active Pharmaceutical Ingredient API Market Research Report 2025
Global Lamivudine API Market Research Report 2025
Global Nucleoside Antiviral Drugs Market Research Report 2025
Global Anti retroviral APIs Market Research Report 2024
Global Antiviral API Lamivudine TDF and TAF Market Research Report 2024
Global Natural APIs Active Pharmaceutical Ingredients Market Research Report 2024
Global Zidovudine API Market Research Report 2025
Global Oncology API Market Research Report 2024
Active Pharmaceutical Ingredient API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antiviral Drug Intermediate Market Research Report 2025
Global Cytotoxic Active Pharmaceutical Ingredients API Market Research Report 2025
Global Anti tuberculosis APIs Market Research Report 2025
Global NSAID API Market Research Report 2024
Global Oseltamivir Phosphate API Market Research Report 2025
Global Enzymatic Synthesis of Active Pharmaceutical Ingredients APIs Market Research Report 2024
Active Pharmaceutical Ingredients API CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biologic Peptide API Market Research Report 2024
Global Letermovir API Market Research Report 2024
Global Rapamycin API Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions